ArticleNature biotechnology2023
Personalized medicine is having its day.
Article in Nature biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies.Orphanet journal of rare diseases · 2026Review
- Why We Need a Dynamic Right to Withdraw in Individualized Antisense Oligonucleotide Therapy Development.Journal of bioethical inquiry · 2026Article
- From precision interventions to precision health.Nature communications · 2025Review
- Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design.Therapeutic innovation & regulatory science · 2025Review
- Review
- A global survey about undiagnosed rare diseases: perspectives, challenges, and solutions.Frontiers in public health · 2025Article
- Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs.Communications biology · 2024Review
- Defining rare conditions in the era of personalized medicine.Nature reviews. Drug discovery · 2023Article
- From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
36973559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.